Skip to main content
Equibles
OTLC logo

OTLC · Oncotelic Therapeutics, Inc. · Metrics

Track OTLC — free

Use OTLC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OTLC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.02 0.00 (-4.86%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing.”
View the 10-Q filed Aug 13, 2026
Market Cap
$9.15M
Shares
457.51M
Volume · Oct 20 227.04K Avg daily vol (3M) 311.29K

OTLC metrics

53 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.02
Market cap
$9.15M

Price action

20 metrics
Price change (1W)
-20.2%
Price change (30D)
-34.1%
Price change (3M)
-58.5%
Price change (6M)
-58.5%
Price change (YTD)
-79.3%
Price change (1Y)
-81.6%
Trailing year
Price change (5Y)
-86.2%
52-week high
$0.11
52-week low
$0.02
Change from 52-week high
-84.9%
Change from 52-week low
+0.0%
Annualized volatility
147.5%
Annualized volatility (3M)
144.9%
Beta
0.9
RSI (14D)
27.1
Price vs SMA 50
-42.6%
Price vs SMA 200
-62.6%
Avg volume (3M)
307,622
Relative volume
1.3
Average dollar volume
$8,696

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
457.51M

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 2,705.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.0
reciprocal yield 2,891.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
2,705.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-9,497.2%
Trailing 12 months
Net margin
-11,290.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$5.72M
Net income (TTM)
$247.58M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.59

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
+39.7%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.3%
Year over year · more shares
Revenue CAGR (3Y)
-65.7%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
+289.3%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
93.6%
Return on assets
62.7%
Debt / equity
0.3
Current ratio
0.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$2.63M
Latest balance sheet
Cash & equivalents
$409,000
Total assets
$394.75M
Total debt
$2.72M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.52M
Capital expenditures (TTM)
—
R&D (TTM)
$4,903
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
29 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 908259 CUSIP 628341109 Visit website Investor relations